One of the most promising niches in the biotech sector from both a technological and a financial standpoint is the realm of gene editing. Technologies such as CRISPR are enabling a new generation of treatments for previously incurable genetic conditions ranging from blood disorders to severe forms of blindness. CRISPR Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT) have emerged as two of the top stocks in the sector. However, the speculative nature of the gene-editing market means that it's never 100% certain which company will succeed or fail in its clinical trials.
As such, even smaller, lesser-known gene-editing companies could be the big winners of the future. One such company is Sangamo Therapeutics (NASDAQ: SGMO), with a market cap of $987 million. Its share prices have gone back and forth for most of the year but have fallen by 21.4% over the past couple weeks and are down 32.3% over the past six months. Let's take a look at whether Sangamo's recent declines are justified and how promising its clinical pipeline is at the moment.